Vijaya Diagnostic Centre (VIJAYA) investor relations material

Executive summary

• Achieved 22.8% year-on-year revenue growth in Q1 FY27, driven by 16.5% volume growth and network expansion, including new hubs in Hyderabad and Bengaluru with advanced imaging tech.

• Strategic focus on organic and inorganic expansion, including the acquisition of Pune's largest B2C diagnostic chain.

• Unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 were approved, showing continued growth in revenue and profitability year-over-year.

Financial highlights

• Consolidated revenue for Q1 FY27 was INR 2,310 Mn (₹23,098.19 lakhs), up 22.8% year-on-year; standalone revenue was ₹21,853.71 lakhs.

• EBITDA grew 34% year-on-year to INR 985 Mn, with margin improving to 42.7%.

• Profit after tax rose 37.6% to INR 531 Mn (₹5,310.11 lakhs); PAT margin at 23%.

• EPS (Basic) for Q1 FY27 was INR 5.2 (₹5.16), up from INR 3.76 in Q1 FY26.

• Revenue per test: INR 403; revenue per footfall/patient: INR 1,860.

Outlook and guidance

• Plans to commission nine more hub centers and 10-12 spoke centers in the next 12 months, with expansion into Karnataka, East India, and densification in AP and Telangana.

• CapEx guidance for expansion is INR 190-195 crore, including land acquisition in AP.

• Confident of sustaining high double-digit growth for FY27 and 15% CAGR over the next 3-5 years.

• EBITDA margin guidance remains above 40% despite expansion drag.

• A dividend of ₹2 per equity share (200%) for FY26 was recommended, subject to shareholder approval.